Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer‑associated thrombosis patients’ healthcare in Spain

• Andrés Muñoz Martín ^[1] ; Antonio Javier Trujillo Santos ^[2] ; Edelmira Martí ^[3] ; Luis Jara Palomares ^[4] ; Pedro Ruíz Artacho ^[5] ; Raquel Macías Montero ^[8] ; Enrique Gallardo ^[9] ; Juan José López Núñez ^[10] ; Elena Brozos Vázquez ^[6] ; Verónica Robles Marinas ^[11] ; Pedro Pérez Segura ^[7]
  1. [1] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  2. [2] Hospital General Universitario Santa Lucía

     Hospital General Universitario Santa Lucía

     Cartagena, España

     
  3. [3] Hospital Clinico Universitario de Valencia

     Hospital Clinico Universitario de Valencia

     Valencia, España

     
  4. [4] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  5. [5] Instituto de Salud Carlos III

     Instituto de Salud Carlos III

     Madrid, España

     
  6. [6] Complexo Hospitalario Universitario de Santiago

     Complexo Hospitalario Universitario de Santiago

     Santiago de Compostela, España

     
  7. [7] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  8. [8] Oncology Department, Hospital de Badajoz, Badajoz, Spain
  9. [9] Oncology Department, Parc Taulí Hospital Universitari, Barcelona, Spain
  10. [10] Internal Medicine Department, Hospital Germans Trias i Pujol, Barcelona, Spain
  11. [11] Hematology Department, Hospital Universitario de Cabueñes, Gijón, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 6, 2024, págs. 1319-1328
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Cancer patients are at risk of venous thromboembolism (VTE), its recurrence, but also at risk of bleeding while anticoagulated. In addition, cancer therapies have been associated to increased VTE risk. Guidelines for VTE treatment in cancer patients recommend low molecular weight heparins (LMWH) or direct oral anticoagulants (DOAC) for the initial treatment, DOAC for VTE short-term treatment, and LMWH or DOAC for VTE long-term treatment. This consensus article arises from a collaboration between diferent Spanish experts on cancer-associated thrombosis. It aims to reach an agreement on a practical document of recommendations for action allowing the healthcare homogenization of cancer-associated thrombosis (CAT) patients in Spain considering not only what is known about VTE management in cancer patients but also what is done in Spanish hospitals in the clinical practice. The text summarizes the current knowledge and available evidence on the subject in Spain and provides a series of practical recommendations for CAT management and treatment algorithms to help clinicians to manage CAT over time.